1. Centers for Disease Control and Prevention. Chronic obstructive pulmonary disease surveillance-United States, 1971–2000. MMWR Survell Summ 2002; 51 (6): 1–16.
2. Диагностика и лечение артериальной гипертензии. Национальные рекомендации. М., 2009.
3. Burt VL, Cutler JA, Higgins M et al. Trends in the Prevalence, Awareness, Treatment, and Control of Hypertension in the Adult US Population. Hypertension 1995; 26: 60–9.
4. Chandy D, Aronow WS, Banach M. Current perspectives on treatment of hypertensive patients with chronic obstructive pulmonary disease. Integr Blood Press Control 2013; 6: 101–9.
5. Кароли Н.А., Ребров А.П. Артериальная гипертензия у пациентов с бронхиальной астмой и хронической обструктивной болезнью легких. Клиницист. 2011; 2: 20–30.
6. Кароли Н.А., Ребров А.П. Хроническая обструктивная болезнь легких и кардиоваскулярная патология. Клиницист. 2007; 1: 13–9.
7. Cazzola M, Noschese P, D’Amato G et al. The Pharmacological Treatment of Uncomplicated Arterial Hypertension in Patients with Airway Dysfunction. Chest 2002; 121 (1): 230–41.
8. Dart RA, Gollub S, Lazar J et al. Treatment of systemic hypertension in patients with pulmonary disease. Chest 2003; 123 (1): 222–43.
9. Herrin MA, Feemster LC, Crothers K et al. Combination antihypertensive therapy among patients with COPD. Chest 2013; 143 (5): 1312–20.
10. Wong CS, Pavord ID, Williams J et al. Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol and terbutaline in asthma. Lancet 1990; 336 (8728): 1396–9.
11. Bear R, Goldstein M, Phillipson E et al. Effect of metabolic alkalosis on respiratory function in pa-tients with chronic obstructive lung disease. Can Med Assoc J 1977; 117 (8): 900–3.
12. Václavík J, Sedlák R, Plachy M et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension 2011; 57 (6): 1069–75.
13. Бова А.А., Лапицкий Д.В. Современные подходы к диагностике и лечению ишемической болезни сердца у больных хронической обструктивной болезнью легких. Мед. новости. 2007; 9: 7–14.
14. Ling Y, Saleem W, Shee CD. Concomitant use of beta-blockers and beta2-agonists. Eur Respir J 2008; 31 (4): 905–6.
15. Egred M, Shaw S, Mohammad B et al. Under-use of beta-blockers in patients with ischaemic heart disease and concomitant chronic obstructive pulmonary disease. QJM 2005; 98 (7): 493–7.
16. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998; 339 (8): 489–97.
17. Albouaini K, Andron M, Alahmar A, Egred M. Beta-blockers use in patients with chronic obstructive pulmonary disease and concomitant cardiovascular conditions. Int J Chron Obstruct Pulmon Dis 2007; 2: 535–40.
18. Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005; 4: CD003566.
19. Van Gestel YR, Hoeks SE, Sin DD et al. Impact of cardioselective beta-blockers on mortality in pa-tients with chronic obstructive pulmonary disease and atherosclerosis. Am J Respir Crit Care Med 2008; 178 (7): 695–700.
20. Etminan et al. Beta-blocker use and COPD mortality: a systematic review and meta-analysis. BMC Pulmonary Medicine 2012; 12: 48.
21. Ekström MP, Hermansson A, Ström KE. Effects of cardiovascular drugs on mortality in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013; 187 (7): 715–20.
22. Dorow P, Thalhofer S, Bethge H et al. Long-term treatment of angina pectoris with bisoprolol or atenolol in patients with chronic obstructive bronchitis: a randomized, double-blind crossover study. J Cardiovasc Pharmacol 1990; 16 (Suppl. 5): S36–S44.
23. Chatterjee SS. The cardioselective and hypotensive effects of bisoprolol in hypertensive asthmatics. J Cardiovasc Pharmacol 1986; 8 (Suppl. 11): S74–S77.
24. Dorow P, Bethge H, Tönnesmann U. Effects of single oral doses of bisoprolol and atenolol on airway function in nonasthmatic chronic obstructive lung disease and angina pectoris. Eur J Clin Pharmacol 1986; 31 (2): 143–7.
25. Van der Woude HJ, Zaagsma J, Postma DS et al. Detrimental effects of beta-blockers in COPD: a concern for non-selective beta-blockers. Chest 2005; 127: 818–24.
26. Cockcroft JR, Pedersen ME. b-Blockade: benefits beyond blood pressure reduction? J Clin Hypertens (Greenwich) 2012; 14 (2): 112–20.
27. Dal Negro R. Pulmonary effects of nebivolol. Adv Cardiovasc Dis 2009; 3 (4): 329–34.
28. Dransfield MT, Rowe SM, Johnson JE et al. Beta-blocker use and the risk of death in hospitalized patients with acute exacerbations of COPD. Thorax 2008; 63: 301–5.
29. Sirak TE, Jelic S, Le Jemtel TH. Therapeutic update: non-selective beta- and alpha-adrenergic block-ade in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. J Am Coll Cardiol 2004; 44 (3): 497–502.
30. Kotlyar E, Keogh AM, Macdonald PS et al. Tolerability of carvedilol in patients with heart failure and concomitant chronic obstructive pulmonary disease or asthma. J Heart Lung Transplant 2002; 21 (12): 1290–5.
31. Jabbour A, Macdonald PS, Keogh AM et al. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. J Am Coll Cardiol 2010; 55 (17): 1780–7.
32. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med 1992; 117 (3): 234–42.
33. Mortensen EM, Copeland LA, Pugh MJV et al. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir Res 2009; 10: 45.
34. Mancini GB, Etminan M, Zhang B et al. Reduction of morbidi-ty and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol 2006; 47 (12): 2554–60.
35. Shrikrishna D, Astin R, Kemp PR, Hopkinson NS. Renin-angiotensin system blockade: a novel the-rapeutic approach in chronic obstructive pulmonary disease. Clin Sci (Lond) 2012; 123 (8): 487–98.
36. Andreas S, Herrmann-Lingen C, Raupach T et al. Angiotensin II blockers in obstructive pulmonary disease: a randomised controlled trial. Eur Respir J 2006; 27 (5): 972–9.
37. Ann Twiss M, Harman E, Chesrown S, Hendeles L. Efficacy of calcium channel blockers as main-tenance therapy for asthma. Br J Clin Pharmacol 2002; 53 (3): 243–9.
38. Itskovitz HD. Alpha 1-blockade for the treatment of hypertension: a megastudy of terazosin in 2214 clinical practice settings. Clin Ther 1994; 16 (3): 490–504.
39. Biernacki W, Flenley DC. Doxazosin, a new alpha-1-antagonist drug, controls hypertension without causing airways obstruction in asthma and COPD. J Hum Hypertens 1989; 3 (6): 419–25.
40. Corriveau ML, Vu-Dinh Minh, Dolan GF. Long-term effects of hydralazine on ventilation and blood gas values in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Am J Med 1987; 83 (5): 886–92.

Н.А.Кароли, А.П.Ребров

Кафедра госпитальной терапии лечебного факультета ГБОУ ВПО Саратовский ГМУ им. В.И.Разумовского Минздрава РФ